Business
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
(TheNewswire) Calgary, Alberta, Canada – TheNewswire - August 19, 2025 - Voy...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Calgary, Alberta, Canada –\n \n\n TheNewswire -\n \n\n August 19, 2025 -\nVoyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF)\n(“\n \n\n Voyageur\n \n\n ” or the “\n \n\n Company\n \n\n ”), a company with a strategic focus\non vertically integrating the barium and iodine contrast markets,\n \n\n is pleased to announce that it has received\nsignificant investor support through the exercise of\n \n\n 14,708,013\n \n\n share purchase warrants\n(“\n \n\n Warrants\n \n\n ”) for gross proceeds of $1,470,801, which included\n1,120,000 Warrants exercised by Ethan Mohan, Executive Vice-President\nof the Company. The Warrants were issued pursuant to a private\nplacement that closed on December 3 and 18, 2024, pursuant to which an\naggregate of 15,231,345 Warrants were issued. The Warrants contained\nan acceleration clause which was triggered as set out in the\nCompany's news release dated July 14, 2025. The remaining 523,332\nWarrants expired as of August 18, 2025 pursuant to the accelerated\nexpiry date.\n \n\n\n\n In addition to the above, the Company also received\ngross proceeds of $215,625 through the exercise of 1,437,500 share\npurchase warrants issued pursuant to a private placement that closed\non March 1, 2024, pursuant to which an aggregate of 6,106,250 share\npurchase warrants were issued. The remaining 4,668,750 share purchase\nwarrants remain unexercised with an expiry date of March 1, 2026.\nThere are now 178,326,125 common shares of the Company issued and\noutstanding.\n \n\n\n\n Brent Willis, Voyageur’s President, CEO and Director,\nexpressed, “We sincerely appreciate the support our existing\ninvestors have placed in us. The warrant exercises will give Voyageur\nadded flexibility in achieving its goals to become a leader in the\nradiology drug market”.\n \n\n\n\n About Voyageur Pharmaceuticals\nLtd.\n \n\n\n\n Voyageur, a Canadian public company trading under the\nsymbol VM on the TSXV, is in development of barium and iodine Active\nPharmaceutical Ingredients (API) and intends to offer\nhigh-performance, cost-effective imaging contrast agents. With a\nstrategic focus on fi...